Total: $50. 15M

Year to Date: $499.72M

Company (Symbol)#*

Partner (Country)

Amt. (M)

Details (Date)


Ablynx NV (Belgium; BR:ABLX)

Boehringer Ingelheim GmbH (Germany)

€3 ($4.1)

For the companies alliance to develop and commercialize Nanobodies (10/4)

Astex Therapeutics Ltd.* (UK)

AstraZeneca plc (UK)

ND

For AstraZeneca's selection of a candidate drug from the collaborative program aimed at identifying small-molecule inhibitors of beta-secretase, a key enzyme implicated in the progression of Alzheimer's disease (10/26)

Depomed Inc. (DEPO)

Janssen Pharmaceutica N.V. (subsidiary of Johnson & Johnson)

$5

For the delivery of a formulation of canagliflozin and metform (10/25)

Flamel Technologies SA (France; FLML)

Merck KGaA (Germany)

€3 ($4.1)

As part of the companies' partnership for the development of an extended-release formulation of interferon beta-1a (10/20)

Incyte Corp. (INCY)

Eli Lilly and Co.

$19

For the start of a Phase IIb trial evaluating INCB28050 for the treatment of rheumatoid arthritis (10/21)

Prosensa Therapeutics BV* (the Netherlands)

GlaxoSmithKline plc (UK)

£7.5 ($11.9)

For the successful safety review in its Phase II open-label, extension trial of GSK2402968 for Duchenne's muscular dystrophy (10/14)

Sucampo Pharmaceuticals Inc. (SCMP)

Abbott Japan Co. Ltd. (Japan)

$5

For the submission of a marketing application to Japanese authorities for approval of Amitiza in chronic idiopathic constipation (10/8)

Vernalis plc (UK; LSE:VER)

Les Laboratoires Servier (France)

€0.75 ($1.045)

As part of a three-year oncology drug discovery collaboration initiated in May 2009; for achieving the desired potency and selectivity criteria in the program (10/7)

Xencor Inc.*

Boehringer Ingelheim GmbH (Germany)

ND

For the regulatory submission of a monoclonal antibody for cancer developed under a 2007 licensing agreement (10/13)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; * Private company. Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed. ** Denotes the date the item ran in BioWorld International.

BR = Brussels Stock Exchange; LSE = London Stock Exchange.